United States - English - NLM (National Library of Medicine)

hbt labs, inc. - paclitaxel (unii: p88xt4is4d) (paclitaxel - unii:p88xt4is4d) - paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. prior therapy should have included an anthracycline unless clinically contraindicated. paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. paclitaxel protein-bound particles for injectable suspension (albumin-bound) is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. paclitaxel protein-bound particles for injectable suspension (albumin-bound) is contraindicated in patients with: - baseline neutrophil counts of < 1,500 cells/mm3 [see warnings and precaut

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paclitaxel, quantity: 150 mg - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer and breast cancer, after failure of standard therapy. treatment of non-small cell lung cancer (nsclc). adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their previous metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paclitaxel, quantity: 100 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer and breast cancer, after failure of standard therapy. treatment of non-small cell lung cancer (nsclc). adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their previous metastatic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - paclitaxel, quantity: 30 mg - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol - primary treatment of ovarian cancer in combination with a platinum agent. treatment of metastatic ovarian cancer and breast cancer, after failure of standard therapy. treatment of non-small cell lung cancer (nsclc). adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that overexpress her-2 and who have not received previous chemotherapy for their previous metastatic disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - paclitaxel - concentrate for soln for inf - 6 mg/ml - paclitaxel

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - paclitaxel - concentrate for solution for infusion - 6 milligram(s)/millilitre - taxanes; paclitaxel

Malta - English - Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg - antineoplastic agents

Malta - English - Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - paclitaxel - concentrate for solution for infusion - paclitaxel 6 mg/ml - antineoplastic agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmachemie b.v. swensweg 5 - paclitaxel - concentrate for solution for infusion - 6mg/ml